Celldex Therapeutics, Inc. — Director's Dealing 2016

Dec 15, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2016-12-14

Reporting Person: McMahon Gerald PhD (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.001 per share	267356	Direct

Footnotes

F1: The number of shares of common stock, par value $0.001 per share ("Common Stock") of Celldex Therapeutics, Inc. ("Issuer") reported on this Form 3 does not reflect the withholding by the Issuer of Common Stock equal to the amount of required tax and other withholdings (the "Withholdings").

F2: On November 28, 2016, in connection with Reporting Person's employment separation with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement with the Issuer whereby Issuer agreed to pay Reporting Person 267,356 shares of Common Stock less required Withholdings. 200,517 shares of Common Stock, less Withholdings, will be issued to Reporting Person ratably over 24 months commencing in the first quarter of 2017 and 66,839 shares of Common Stock, less Withholdings will be issued not later than March 15, 2017.